Previous close | 136.10 |
Open | 136.08 |
Bid | 135.86 x 0 |
Ask | 135.96 x 0 |
Day's range | 135.62 - 136.30 |
52-week range | 132.78 - 161.20 |
Volume | |
Avg. volume | 3,503 |
Market cap | 327.986B |
Beta (5Y monthly) | 0.53 |
PE ratio (TTM) | 21.69 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 4.55 (3.34%) |
Ex-dividend date | 20 May 2024 |
1y target est | N/A |
Johnson & Johnson (NYSE: JNJ) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration (SC amivantamab) for all currently approved or submitted indications of intravenous (IV) RYBREVANT® (amivantamab-vmjw) in certain patients with non-small cell lung cancer (NSCLC).
Johnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the Phase 2 DAHLIAS dose-ranging study of nipocalimab in adult patients living with Sjögren's disease (SjD). Response was demonstrated as early as Week 4 and continued to increase throughout the 24-week treatment period compared with patients recei
Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated with TALVEY® (talquetamab-tgvs) maintained high overall response rates (ORR) and durable responses, irrespective of whether they had received prior T-cell redirection therapy.1 These data, featured in a poster presentation at the 2024 European